Roche Holding Ltd (RO) AI Stock Analysis

• Market Cap: CHF240.33B
• Dividend Yield: 2.88%
• Average Volume (3M): 28.08K
• Price to Earnings (P/E): 20.3
• Beta (1Y): 1.34
• Revenue Growth: 4.77%
• EPS Growth: -11.07%
• Country: CH
• Employees: 103,249
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 8.38
• Shares Outstanding: 106,691,000
• 10 Day Avg. Volume: 29,793
• 30 Day Avg. Volume: 28,076
• PEG Ratio: 0.36
• Price to Book (P/B): 7.73
• Price to Sales (P/S): 4.25
• P/FCF Ratio: 18.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 20.03
• Revenue Forecast (FY): CHF62.70B

• Rating: 78 Outperform
• Price Target: CHF353.00 ▲(5.31% Upside)
• Action: Reiterated Date: 01/31/26
• Date: Action: Reiterated 01/31/26

The score is driven primarily by strong financial quality (high profitability and solid free cash flow) and supportive technical momentum (price above key moving averages with positive MACD). Earnings call outlook is constructive with growth and margin expansion guidance, though tempered by FX, China diagnostics headwinds, LOE pressure, and some safety/regulatory uncertainty. Valuation is reasonable but not cheap at a 22.2 P/E, with a supportive 2.7% dividend yield.

Positive Factors

Free Cash Flow & Profitability

Consistent high operating cash flow and robust free cash flow provide durable funding for R&D, dividend increases and capital investment. Strong gross and EBIT margins support reinvestment capacity and financial resilience, enabling sustained product development and shareholder returns.

Deep, De‑risked Pharma Pipeline

A larger, advancing NME cohort plus multiple approvals materially raises the company’s risk‑adjusted future revenue potential. Progress across oncology, immunology and CNS increases probability of durable new product flows, supporting medium‑term revenue diversification beyond LOE exposures.

Diagnostics Installed Base & Product Innovation

Diagnostics innovation (new assays, mass spec and high‑throughput NGS) expands addressable markets and supports recurring reagent and service revenue from installed instruments. Regulatory designations that broaden test access strengthen long‑term consumables annuity economics and clinical adoption.

Negative Factors

China Diagnostics Pricing Reforms

Sustained Chinese healthcare pricing reforms are a structural headwind for diagnostics revenue and margins in a major market. Prolonged lower pricing and reimbursement can permanently reduce consumables ASPs and slow instrument placement economics, requiring margin and product mix offsets elsewhere.

Loss of Exclusivity (LOE) & Biosimilars

Material LOE and impending biosimilar competition threaten recurring revenue from established brands. Revenue erosion from LOE is a multi‑year structural risk that pressures growth and forces reliance on new launches and the pipeline to replace lost cash flow and protect margins.

Elevated Leverage vs. Prior Years

Leverage materially above historical lows reduces financial flexibility for large M&A, aggressive buybacks or cushioning cyclical shocks. While manageable, higher net debt increases interest and refinancing sensitivity, constraining tactical capital allocation if growth slows or cash conversion weakens.

Roche Holding Ltd Business Overview & Revenue Model

Company Description

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.

How the Company Makes Money

Roche makes money mainly by selling products and services through its Pharmaceuticals and Diagnostics divisions. In Pharmaceuticals, Roche generates revenue from sales of patented prescription medicines to hospitals, clinics, wholesalers, pharmacies, and governments/health systems. Earnings are driven by (1) demand and pricing/reimbursement for its branded therapies, (2) the mix of high-value specialty medicines (notably in oncology and immunology), and (3) lifecycle management such as line extensions, new indications, and combination regimens. Roche also earns from collaboration-related income where applicable (e.g., upfront payments, milestone payments, and royalties) tied to partnered drug development or commercialization arrangements; if a specific partnership’s financial contribution is not publicly broken out, it is not separately quantifiable. In Diagnostics, Roche generates revenue from (1) instrument placements/sales (laboratory analyzers and point-of-care devices) and (2) recurring consumables such as test reagents, kits, and associated supplies used on those instruments—typically a high-frequency, recurring revenue stream once an installed base is established. Additional revenue can come from service and support (maintenance contracts, training, and other customer services) and software/digital solutions that support laboratory workflow and data management; if a given service line’s revenue is not separately disclosed, it is not independently itemized. Across both divisions, key factors influencing earnings include product innovation and successful R&D output, regulatory approvals, patent protection and competition (including biosimilars/generics), payer reimbursement decisions, geographic and customer mix, and the scale benefits from Roche’s global commercial and manufacturing footprint.

Roche Holding Ltd Financial Statement Overview

Summary

Strong profitability profile (high gross margins and solid EBIT margins) and robust free cash flow generation. Offsetting factors include uneven revenue/earnings trajectory across years, some margin volatility, and a higher (though manageable) leverage profile versus earlier years.

Income Statement

Roche shows strong underlying profitability, with consistently high gross margins (~69–74%) and solid operating profitability (EBIT margin generally in the low-to-high 20s). After a soft 2024 in earnings (net margin ~13%), 2025 rebounded sharply (net margin ~21%) alongside a very strong reported revenue increase. Key watch-outs are uneven top-line growth (including prior declines) and some margin volatility year-to-year.

Balance Sheet

The balance sheet is generally sound for a large pharma, with equity in the ~CHF 29–36B range and debt-to-equity mostly around ~0.9–1.1 (2025 ~0.94). Leverage is meaningfully higher than 2020 (when debt-to-equity was ~0.42), which reduces flexibility, but it has improved from the peak around 2021–2024 (above ~1.1 at times). Overall, leverage looks manageable, though not conservative.

Cash Flow

Cash generation is solid: operating cash flow is consistently strong (~CHF 16–21B) and free cash flow remains robust (~CHF 11–16B). Free cash flow has covered a large portion of earnings (roughly ~63–79% across the period), supporting quality of profits, but conversion weakened somewhat in 2025 versus 2024 as operating cash flow declined while net income rose. Free cash flow growth has also been uneven, with several negative years despite the recent improvement.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	61.52B	62.40B	60.44B	65.81B	62.80B
Gross Profit	45.23B	46.11B	44.08B	47.88B	43.10B
EBITDA	22.66B	16.62B	18.41B	20.80B	22.19B
Net Income	12.88B	8.28B	11.50B	12.42B	13.93B
Balance Sheet
Total Assets	100.70B	101.80B	90.47B	88.15B	92.32B
Cash, Cash Equivalents and Short-Term Investments	15.48B	17.32B	10.51B	9.77B	13.03B
Total Debt	33.19B	36.35B	30.78B	26.54B	32.55B
Total Liabilities	62.82B	65.64B	57.20B	56.14B	63.97B
Stockholders Equity	33.80B	31.77B	29.32B	27.99B	24.49B
Cash Flow
Free Cash Flow	14.08B	15.09B	11.45B	13.34B	16.02B
Operating Cash Flow	17.83B	20.09B	16.09B	17.89B	20.57B
Investing Cash Flow	-8.71B	-11.39B	-10.64B	-3.57B	-6.55B
Financing Cash Flow	-10.18B	-6.82B	-4.24B	-15.72B	-12.70B

Roche Holding Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 335.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:RO, the sentiment is Negative. The current price of 335.2 is below the 20-day moving average (MA) of 342.87, below the 50-day MA of 346.94, and above the 200-day MA of 297.87, indicating a neutral trend. The MACD of -9.47 indicates Positive momentum. The RSI at 27.87 is Positive, neither overbought nor oversold. The STOCH value of 0.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:RO.

Roche Holding Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RO	78 Outperform	CHF240.33B	20.28	―	2.88%	4.77%	-11.07%
NOVN	78 Outperform	CHF220.01B	18.30	―	3.18%	7.62%	-18.33%
ALC	72 Outperform	CHF29.09B	38.35	4.44%	0.44%	0.39%	-12.46%
SDZ	66 Neutral	$26.75B	32.85	2.64%	1.02%	―	―
GALD	63 Neutral	CHF33.37B	75.41	―	0.09%	6.22%	―
LONN	56 Neutral	CHF31.80B	19.54	―	0.75%	5.93%	29.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%